Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer

This article was originally published in The Tan Sheet

Executive Summary

U.S. Consumer Health sales of $399 mil. declined 2% in the second quarter due to competition from private label ranitidine (Zantac 75), the company reports July 24. The figures, which combine Pfizer and Warner-Lambert's consumer health divisions, are the first reported since Pfizer acquired W-L for roughly $90 bil. (1"The Tan Sheet" Feb. 14, p. 5). Six-month U.S. sales of $821 mil. also declined 1.8%. However, Pfizer notes its oral care business performed well. IRI data for the 52 weeks ending June 18 show Listerine sales totaled $301.4 mil. (up 7.4%), while Zantac 75 sales were down 17.1% to $141 mil. Consolidated sales for the quarter totaled $7.04 bil., up 8%

You may also be interested in...



Warner-Lambert/Pfizer Consumer Healthcare Sales Top $3.5 Bil.

The combination of Warner-Lambert and Pfizer will create a firm with consumer healthcare sales of over $3.5 bil., based on 1999 results, with W-L contributing roughly $3 bil. of the total.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel